Vertex Pharmaceuticals Incorporated (VRTX)
VRTX Stock Price Chart
Explore Vertex Pharmaceuticals Incorporated interactive price chart. Choose custom timeframes to analyze VRTX price movements and trends.
VRTX Company Profile
Discover essential business fundamentals and corporate details for Vertex Pharmaceuticals Incorporated (VRTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Jul 1991
Employees
6.10k
Website
https://www.vrtx.comCEO
Reshma Kewalramani
Description
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
VRTX Financial Timeline
Browse a chronological timeline of Vertex Pharmaceuticals Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is $4.73, while revenue estimate is $3.23bn.
Earnings released on 4 May 2026
EPS came in at $4.47 surpassing the estimated $4.24 by +5.42%, while revenue for the quarter reached $2.99bn , missing expectations by -0.24%.
Earnings released on 12 Feb 2026
EPS came in at $5.03 falling short of the estimated $5.11 by -1.57%, while revenue for the quarter reached $3.19bn , beating expectations by +0.18%.
Earnings released on 3 Nov 2025
EPS came in at $4.80 surpassing the estimated $4.57 by +5.03%, while revenue for the quarter reached $3.08bn , beating expectations by +0.55%.
Earnings released on 4 Aug 2025
EPS came in at $4.52 surpassing the estimated $4.29 by +5.36%, while revenue for the quarter reached $2.96bn , beating expectations by +2.01%.
Earnings released on 5 May 2025
EPS came in at $4.06 falling short of the estimated $4.25 by -4.47%, while revenue for the quarter reached $2.77bn , missing expectations by -3.20%.
Earnings released on 10 Feb 2025
EPS came in at $3.98 falling short of the estimated $4.02 by -1.00%, while revenue for the quarter reached $2.91bn , beating expectations by +4.59%.
Earnings released on 4 Nov 2024
EPS came in at $4.38 surpassing the estimated $4.14 by +5.80%, while revenue for the quarter reached $2.77bn , beating expectations by +3.22%.
Earnings released on 1 Aug 2024
EPS came in at -$12.83 falling short of the estimated -$11.63 by -10.32%, while revenue for the quarter reached $2.63bn , missing expectations by -1.09%.
Earnings released on 6 May 2024
EPS came in at $4.76 surpassing the estimated $4.06 by +17.24%, while revenue for the quarter reached $2.69bn , beating expectations by +4.10%.
Earnings released on 5 Feb 2024
EPS came in at $4.20 surpassing the estimated $4.10 by +2.44%, while revenue for the quarter reached $2.52bn , beating expectations by +0.19%.
Earnings released on 6 Nov 2023
EPS came in at $4.08 surpassing the estimated $3.97 by +2.77%, while revenue for the quarter reached $2.48bn , missing expectations by -0.59%.
Earnings released on 1 Aug 2023
EPS came in at $3.89 surpassing the estimated $3.88 by +0.26%, while revenue for the quarter reached $2.49bn , beating expectations by +3.05%.
Earnings released on 1 May 2023
EPS came in at $3.05 surpassing the estimated $3.00 by +1.67%, while revenue for the quarter reached $2.37bn , beating expectations by +1.62%.
Earnings released on 7 Feb 2023
EPS came in at $3.76 surpassing the estimated $3.51 by +7.12%, while revenue for the quarter reached $2.30bn , missing expectations by -0.09%.
Earnings released on 27 Oct 2022
EPS came in at $4.01 surpassing the estimated $3.64 by +10.16%, while revenue for the quarter reached $2.33bn , beating expectations by +4.68%.
Earnings released on 4 Aug 2022
EPS came in at $3.60 surpassing the estimated $3.48 by +3.45%, while revenue for the quarter reached $2.20bn , beating expectations by +3.02%.
Earnings released on 5 May 2022
EPS came in at $3.52 surpassing the estimated $3.49 by +0.86%, while revenue for the quarter reached $2.10bn , beating expectations by +1.09%.
Earnings released on 26 Jan 2022
EPS came in at $3.37 surpassing the estimated $3.30 by +2.12%, while revenue for the quarter reached $2.07bn , beating expectations by +3.50%.
Earnings released on 2 Nov 2021
EPS came in at $3.56 surpassing the estimated $3.08 by +15.58%, while revenue for the quarter reached $1.98bn , beating expectations by +7.47%.
Earnings released on 29 Jul 2021
EPS came in at $3.11 surpassing the estimated $2.69 by +15.61%, while revenue for the quarter reached $1.79bn , beating expectations by +4.38%.
VRTX Stock Performance
Access detailed VRTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
